Key facts
- Luxvitae Therapeutics’s last known valuation is $41.9M (Jan 2025).
- It has raised $14.0M across 1 recorded rounds; the latest was Early Stage VC ($8.5M) in Nov 2024.
- Luxvitae Therapeutics has filed 1 Form D with the SEC, most recently Jan 2025 ($8.5M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Luxvitae Therapeutics
Funding rounds
1 roundsAbout Luxvitae Therapeutics
Operator of a biotechnology company intended to give therapies for various medical conditions. The company aims to improve patient outcomes through cutting-edge treatments and technologies, enabling patients to get more effective, and less toxic therapies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 7
- Website
- luxvither.com/
- Ownership
- Privately Held (backing)
Luxvitae Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luxvitae Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luxvitae Therapeutics in its N-PORT filings yet. We sweep new filings monthly.